January 15, 2026 · Phase 2 readout
FDMT Phase 2 readout: a negative outcome, -13.1%
On January 15, 2026, 4D-310 — 4D Molecular Therapeutics, Inc. (Fabry Disease) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -13.1% in the window around the event. It had already run -34.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$8.76
1d before
$7.61
Event day
$7.55
1d after
$7.62
5d after
Pre-catalyst setup
-34.9%
30-day run-up
10231%
30-day volatility
0.8×
volume spike